Volume 8 Issue 1, Jan 2023

ISSN: 2095-9907 

EISSN: 2059-23635 

2023 impact factor 40.8 

 (Clarivate Analytics, 2024)
Volume 8 Issue 1, Jan 2023:
Article
Tripterin liposome relieves severe acute respiratory syndrome as a potent COVID-19 treatment
Haiying Que,Weiqi Hong  ORCID: orcid.org/0000-0003-1668-2301,Tianxia Lan,Hao Zeng,Li Chen,Dandan Wan,Zhenfei Bi,Wenyan Ren  ORCID: orcid.org/0000-0001-6333-8496,Min Luo  ORCID: orcid.org/0000-0002-6875-7945,Jingyun Yang,Cai He,Ailing Zhong &…Xiawei Wei  ORCID: orcid.org/0000-0002-6513-6422 
For coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 15–30% of patients are likely to develop COVID-19-related acute respiratory distress syndrome (ARDS). There are still few effective and well-understood therapies available. Novel variants and short-lasting immunity are posing challenges to vaccine efficacy, so finding antiviral and antiinflammatory treatments remains crucial. Here, tripterin (TP), a traditional Chinese medicine, was encapsulated into liposome (TP lipo) to investigate its antiviral and antiinflammatory effects in severe COVID-19. By using two severe COVID-19 models in human ACE2-transgenic (hACE2) mice, an analysis of TP lipo’s effects on pulmonary immune responses was conducted. Pulmonary pathological alterations and viral burden were reduced by TP lipo treatment. TP lipo inhibits SARS-CoV-2 replication and hyperinflammation in infected cells and mice, two crucial events in severe COVID-19 pathophysiology, it is a promising drug candidate to treat SARS-CoV-2-induced ARDS.